Mp78-05 Steerable Ureteroscopic Renal Evacuation Device, a Single Center Experience

You have accessJournal of UrologyStone Disease: Surgical Therapy (Including ESWL) V (MP78)1 May 2024MP78-05 STEERABLE URETEROSCOPIC RENAL EVACUATION DEVICE, A SINGLE CENTER EXPERIENCE Andrea J. Moyer, Luke Griffiths, Gregory Mullen, Leah Beland, Matthew Mikula, Tareq Aro, Jared Winoker, David Hoenig, Zeph Okeke, and Arun Rai Andrea J. MoyerAndrea J. Moyer , Luke GriffithsLuke Griffiths , Gregory MullenGregory Mullen , Leah BelandLeah Beland , Matthew MikulaMatthew Mikula , Tareq AroTareq Aro , Jared WinokerJared Winoker , David HoenigDavid Hoenig , Zeph OkekeZeph Okeke , and Arun RaiArun Rai View All Author Informationhttps://doi.org/10.1097/01.JU.0001008856.05210.73.05AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: In the past decades, the prevalence of nephrolithiasis has increased globally. The goal of surgical treatment of kidney stones is to maximize stone free rate (SFR) while minimizing morbidity. Kim et al. recently reported SFR after ureteroscopy (URS) of 49.6% in renal stones. Residual fragments can lead to significant stone events such as stone growth, pain, infection, or additional procedures. For large stone burdens, percutaneous nephrolithotomy (PCNL) is preferred to achieve this goal. PCNL is invasive and those with contraindications have limited treatment options. The CVAC™ calculus vacuum aspiration catheter is a steerable ureteroscopic renal evacuation (SURE) device used to remove small stone fragments after laser lithotripsy designed to improve stone free outcomes.We sought to report our experience using a novel SURE device in the management of nephrolithiasis and describe its efficacy and safety. METHODS: A retrospective chart review of all patients at our institution undergoing SURE from January 2022 through August 2023 was performed. Use of SURE was at the discretion of the surgeon. For all patients, URS with laser lithotripsy was performed until stone fragments were less than 2mm in size. Stone volumes were calculated for spheroids using formulas based on maximum stone diameter. Postoperative imaging was performed with either CT or ultrasound (US) with the majority performed at two months. SFR was defined as 4mm (Table 1). Only two intraoperative complications of minor ureteral tears managed with stents were reported. Overall, there were eight postoperative complications. Five patients (5.5%) developed postoperative sepsis, two patients developed urinary tract infections, and one patient had stent migration requiring return to the operating room for replacement. Eleven patients (12%) had second stage procedures to treat their stone disease. CONCLUSIONS: SURE is a safe and effective treatment option for patients undergoing URS with high SFR comparable to URS alone. SURE was also associated with low morbidity, even when treating large volume stone disease. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e1264 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Andrea J. Moyer More articles by this author Luke Griffiths More articles by this author Gregory Mullen More articles by this author Leah Beland More articles by this author Matthew Mikula More articles by this author Tareq Aro More articles by this author Jared Winoker More articles by this author David Hoenig More articles by this author Zeph Okeke More articles by this author Arun Rai More articles by this author Expand All Advertisement PDF downloadLoading ...